Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | NT-I7 |
Trade Name | |
Synonyms | GX-I7|rhIL-7-hyFc|IL-7-hyFc|Efineptakin alfa|Hyleukin |
Drug Descriptions |
NT-I7 is a fusion protein comprised of a recombinant interleukin-7 (IL-7) linked to a hybrid immunoglobulin Fc region, which potentially has increased stability and enhances anti-tumor immune response (Journal of Clinical Oncology 37, no. 15_suppl, Abs nr: e13516). |
DrugClasses | |
CAS Registry Number | 2026634-47-7 |
NCIT ID | C151927 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Atezolizumab + NT-I7 | Atezolizumab NT-I7 | 0 | 2 |
Dexamethasone + NT-I7 | Dexamethasone NT-I7 | 0 | 1 |
Nivolumab + NT-I7 | NT-I7 Nivolumab | 0 | 1 |
NT-I7 | NT-I7 | 0 | 3 |
NT-I7 + Pembrolizumab | NT-I7 Pembrolizumab | 0 | 2 |
NT-I7 + Radiotherapy + Temozolomide | NT-I7 Radiotherapy Temozolomide | 0 | 1 |